AVDL
AVADEL PHARMACEUTICALS PLCCompany Information
- Company Name
- AVADEL PHARMACEUTICALS PLC
- CIK
- CIK0001012477
- Category
- Large accelerated filer
- Ticker: Exchange
- AVDL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AVDL
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-21
- Last sale
- 2026-02-13
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 11,112,052
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 68,982,243
- Shares outstanding
- 97,104,000
- Ownership
- 71.04%
Earnings Market Reaction
- Filing date
- 2025-11-04
- Price on filing date
- —
- 1-month reaction
- 13.70%
- 3-month reaction
- 13.76%
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 80 | 63 | 56 | 51 | 29 | 29 | 36 | 31 | 52 | 50 | 83 | 74 | ||||||
| Marketable Securities Current | 12 | 18 | 10 | 22 | 37 | 43 | 53 | 74 | 101 | 111 | 18 | 23 | ||||||
| Accounts Receivable Net Current | 42 | 41 | 42 | 34 | 37 | 33 | 23 | 12 | 6 | 2 | - | 0 | ||||||
| Inventory Net | 24 | 23 | 20 | 20 | 16 | 13 | 12 | 10 | 5 | 1 | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 14 | 13 | 11 | 6 | 8 | 7 | 11 | 7 | 6 | 7 | 6 | 2 | ||||||
| Assets Current | 172 | 159 | 139 | 134 | 127 | 126 | 136 | 134 | 172 | 171 | 109 | 101 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | 2 | ||||||
| Goodwill | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | ||||||
| Other Assets Noncurrent | 7 | 8 | 9 | 11 | 12 | 12 | 12 | 10 | 10 | 11 | 11 | 11 | ||||||
| Assets | 199 | 187 | 168 | 164 | 158 | 158 | 168 | 165 | 203 | 201 | 141 | 133 | ||||||
Liabilities Current | ||||||||||||||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | 21 | 21 | 21 | 38 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable Current | 13 | 10 | 9 | 7 | 8 | 10 | 19 | 11 | 13 | 12 | 10 | 8 | ||||||
| Accrued Liabilities Current | 44 | 43 | 41 | 41 | 34 | 34 | 28 | 24 | 18 | 18 | 8 | 7 | ||||||
| Senior Notes Current | - | - | - | - | - | - | - | 0 | - | - | - | 38 | ||||||
| Other Liabilities Current | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | ||||||
| Liabilities Current | 62 | 57 | 51 | 49 | 43 | 45 | 48 | 37 | 54 | 52 | 79 | 56 | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 93 | 92 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Senior Long Term Notes | - | - | - | - | - | - | - | 0 | 0 | - | - | 92 | ||||||
| Liabilities | 101 | 96 | 94 | 90 | 84 | 87 | 90 | 77 | 93 | 58 | 179 | 154 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 910 | 903 | 897 | 892 | 887 | 880 | 874 | 855 | 852 | 849 | 603 | 590 | ||||||
| Retained Earnings Accumulated Deficit | -790 | -790 | -799 | -794 | -789 | -787 | -773 | -745 | -717 | -680 | -616 | -585 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -24 | -24 | -24 | -25 | -24 | -24 | -24 | -23 | -26 | -26 | -26 | -26 | ||||||
| Stockholders Equity | 98 | 91 | 74 | 74 | 75 | 70 | 78 | 88 | 110 | 143 | -38 | -21 | ||||||
| Liabilities And Stockholders Equity | 199 | 187 | 168 | 164 | 158 | 158 | 168 | 165 | 203 | 201 | 141 | 133 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 5 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 5 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 97 | 97 | 97 | 97 | 96 | 96 | 96 | 90 | 89 | 89 | 64 | 63 | ||||||
| Shares Outstanding | 97 | 97 | 97 | 97 | 96 | 96 | 96 | 90 | 89 | 89 | 64 | 63 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAVADEL PHARMACEUTICALS PLC (AVDL) — SEC Financial Statements & Analysis
AVADEL PHARMACEUTICALS PLC (AVDL) is a pharmaceutical preparations company. AVADEL PHARMACEUTICALS PLC trades on Nasdaq as: AVDL. AVADEL PHARMACEUTICALS PLC (AVDL)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-04. Based on that filing, On profitability, AVADEL PHARMACEUTICALS PLC posts a gross margin of 94.91%, an operating margin of 1.82%, a net margin of -0.11%, a Return on Equity (ROE) of -0.32%, a Return on Assets (ROA) of -0.16%, and a Return on Invested Capital (ROIC) of 1.07%. Per share, it reports EPS of $-0.00, diluted EPS of $-0.00, free cash flow per share of $0.35, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 79.88% year-over-year, net income growth of -99.62% year-over-year, and EPS growth of -99.62% year-over-year. On the balance sheet, it maintains a current ratio of 2.76x, a quick ratio of 2.14x, working capital of $109.74M, a debt-to-equity ratio of 1.03x, a debt ratio of 0.51, an interest coverage ratio of 0.47x, free cash flow of $34.35M (TTM), and net debt of $-79.81M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.00
- ROE TTM
- -0.32%
- ROA TTM
- -0.16%
- Debt To Equity
- 1.03x
- Free Cash Flow TTM
- $34.35M
- Net Revenue TTM Growth 1Y
- 79.88%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AVADEL PHARMACEUTICALS PLC in?
AVADEL PHARMACEUTICALS PLC (AVDL) operates in the Pharmaceutical Preparations industry.
What exchange does AVDL trade on?
AVADEL PHARMACEUTICALS PLC (AVDL) trades on the Nasdaq.
When was AVADEL PHARMACEUTICALS PLC (AVDL)'s most recent SEC filing?
AVADEL PHARMACEUTICALS PLC (AVDL)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-04.
What is AVDL's EPS (earnings per share)?
AVADEL PHARMACEUTICALS PLC (AVDL)'s trailing twelve month EPS is $-0.00 as of 2025-09-30.
What is AVDL's ROE (return on equity)?
AVADEL PHARMACEUTICALS PLC (AVDL)'s trailing twelve month Return on Equity (ROE) is -0.32% as of 2025-09-30.
What is AVDL's ROA (return on assets)?
AVADEL PHARMACEUTICALS PLC (AVDL)'s trailing twelve month Return on Assets (ROA) is -0.16% as of 2025-09-30.
What is AVDL's ROIC (return on invested capital)?
AVADEL PHARMACEUTICALS PLC (AVDL)'s trailing twelve month Return on Invested Capital (ROIC) is 1.07% as of 2025-09-30.